Bariatric Surgical Choices

The Current State of Surgical Intervention in Management of Morbid Obesity

Goals

• Obesity over the last decade
• Surgery has become a safer management strategy
• Surgical options for management
Goals

- Obesity over the last decade
- Surgery has become a safer management strategy
- Surgical options for management

Obesity in the last decade
An overweight America comes with a hefty price tag

Fat burden falls on taxpayers
By Nancy Hellmich
USA TODAY

Americans' extra weight costs the nation as much as $3 billion in annual medical bills, and the government pays about half of that amount, a federally funded study shows.

This is the highest estimate yet of the medical costs of overweight and obesity. It's comparable to the annual medical bill for smoking, which was estimated at about $40 billion a few years ago.

The new study by three economists, paid for by the U.S. Centers for Disease Control and Prevention, includes direct medical costs but not indirect costs such as time of work. Almost 50% of people in the USA are either overweight or obese. Overweight is defined as roughly 10 to 30 pounds over a healthy weight, obesity is 30 or more pounds over. People who weigh too much are at an increased risk of heart disease, diabetes, some types of cancer and other illnesses.

The researchers used existing data to compare medical costs for overweight and obese people with the costs for people of normal weight. Their findings, in today's online issue of Health Affairs:
- Overall, annual medical costs for an obese person are about 37% more, or $732 higher, than the costs for someone of normal weight.
- An obese recipient of Medicare (a program for the elderly) costs $4,146 more per year than one of healthy weight.
- But these numbers, he said, don't take into account the federal government, are financing half the cost, a relief to the nation that obesity is not solely a personal issue.

Others say this study is a wake-up call. "The government is going to get slammed in future obesity costs if it doesn't address the problem now," says Sharon Vold of the University of Virginia Medical School. She has studied the economics of obesity.

"As the population ages and the prevalence of obesity continues to rise, Medicare is going to be picking up the health care tab for these people," she says.
Obesity Trends Among U.S. Adults

"Maps of Trends in Diagnosed Diabetes and Obesity" April 2017, CDC’s Division of Diabetes Translation

1985

1990

No Data | <10% | 10%–14%
Obesity Trends Among U.S. Adults
"Maps of Trends in Diagnosed Diabetes and Obesity" April 2017, CDC's Division of Diabetes Translation
1995

2000
Obesity Trends Among U.S. Adults
"Maps of Trends in Diagnosed Diabetes and Obesity" April 2017, CDC's Division of Diabetes Translation
2005

Obesity Trends Among U.S. Adults
"Maps of Trends in Diagnosed Diabetes and Obesity" April 2017, CDC's Division of Diabetes Translation
2007
Obesity Trends Among U.S. Adults

“Maps of Trends in Diagnosed Diabetes and Obesity” April 2017, CDC’s Division of Diabetes Translation

2010

Prevalence of Obesity

“Maps of Trends in Diagnosed Diabetes and Obesity” April 2017, CDC’s Division of Diabetes Translation

By 2010, no state has a prevalence of obesity less than 20%

• 36 states had a prevalence equal to or greater than 25%
• 12 states had a prevalence equal to or greater than 30%.
**ASMBS Consensus & American College of Surgeons**

 Clinically severe obesity

- Life threatening condition
- Shortens life expectancy
- Associated with significant comorbid conditions
- “The diseases associated with morbid obesity markedly reduce the odds of attaining an average life span and raise annual mortality tenfold or more.”

---

**American Heart Association**

*Scientific Statement AHA March 2011*

- “Bariatric surgery can result in long-term weight loss and significant reductions in cardiac and other risk factors for some severely obese adults.”
- First statement by the American Heart Association focused solely on bariatric surgery and cardiac risk factors.
American Association of Clinical Endocrinologists
AACE Task Force on Obesity July 2011

• Declared that “there is significant clinical evidence to declare obesity as a disease state...Surgical therapy for obesity, or ‘bariatric surgery,’ is indicated for certain high-risk patients,” having “‘clinically severe obesity.’

• “The comorbidities of severe obesity affect all the major organ systems of the body. Surgically induced weight loss will substantially improve or reverse the vast majority of these adverse effects from severe obesity.”

American Diabetes Association
2011 Position Statement: Standards of Medical Care in Diabetes

• “Bariatric surgery may be considered for adults with BMI > 35 kg/m2 and type 2 diabetes, especially if the diabetes or associated comorbidities are difficult to control with lifestyle and pharmacologic therapy.”
1991 NIH consensus

• “Experience with drug therapy for clinically severe obesity has been disappointing...”

International Diabetes Federation

2011 Position Statement

• “Bariatric surgery is an appropriate treatment for people with type 2 diabetes and obesity... Surgery should be an accepted option in people who have type 2 diabetes and a BMI of 35 or more. Surgery should be considered as an alternative treatment option in patients with a BMI between 30 and 35 when diabetes cannot be adequately controlled by optimal medical regimen, especially in the presence of other major cardiovascular disease risk factors.”
Obesity causes Metabolic Disease

- Liver disease
- Gallbladder disease
- Asthma
- Heart disease
- High blood pressure
- Type 2 diabetes
- GERD
- Menstrual dysfunction
- Fertility problems
- Osteoarthritis
- Gout
- Liver failure
- Stroke
- Cancer

Obesity Therapy

- Dietary therapy
- Physical activity
- Behavior therapy
- Pharmacotherapy
- Surgery
Goals

- Obesity over the last decade
- Surgery has become a safer management strategy
- Surgical options for management
Surgery has become a safer management strategy*

- Risk of death 0.1%
- Lap chole 0.7%
- Hip replacement 0.93%
- Overall Risk of complications 4%
- Laparoscopic operations increased from 20.1% in 2003 to 90.2% in 2008
- Patient with BMI > 30 have a 50-100% increased risk of death
- Roux Y Bypass patients have risk reduction by 30-40%


Surgery has become a safer management strategy
Surgery has become a safer management strategy

- Technology allows surgeons to operate with less invasive techniques
- Faster return to normal physiology
- Shorter hospitalizations
- Better preoperative management
- Optimize co morbid conditions
- Better patient education
- Quality measures
Open Surgery

Large 10 to 14 inch incisions are used to access the stomach and intestines for the surgery.

Laparoscopy
Minimally Invasive Surgery

Surgeons manipulate surgical instruments from outside the body while viewing the procedure on the video monitors.
Robotic Surgery

3 Dimensional high definition imaging.

Surgeon directs precision movement of the tiny instruments, using console controls.

Robotic system scales and replicates movements, while eliminating hand tremors.
Endoscopic Surgery

Innovations in endoscopic technology allow basic tissue manipulation and implantation of devices to assist in weight loss.

Goals

- Obesity over the last decade
- Surgery has become a safer management strategy
- Surgical options for management
Goals

• Obesity over the last decade
• Surgery has become a safer management strategy
• Surgical options for management

Surgical options for management

Restrictive
• Adjustable gastric banding
• Vertical gastric sleeve
• Endoscopically placed intragastric balloons

Restrictive and Malabsorptive
• Biliopancreatic diversion (BPD) Duodenal Switch
• RouxY gastric bypass (RYGB)
Surgical options for management

Restrictive
• Adjustable gastric banding
• Vertical gastric sleeve
• Endoscopically placed intragastric balloons

Restrictive and Malabsorptive
• Biliopancreatic diversion (BPD) Duodenal Switch
• RouxY gastric bypass (RYGB)

Restrictive
• Restrictive procedures alter the sensation of satiety
  • Limits total PO intake
  • Create a net negative calorie balance
  • Increase the duration of satiety
  • Does not alter absorption
Restrictive

- At risk for GERD
- Have a higher risk of inadequate weight loss
- Conversion to more effective operations
- Subject to patient’s dietary compliance – patients will absorb every calorie they consume
- Probably require significantly greater follow up coaching, dietary counseling
- May require adjustments (ie Lap Band) or extraction (intragastric balloons)
Intragastric Balloons
Surgical options for management

Restrictive
• Adjustable gastric banding
• Vertical gastric sleeve
• Endoscopically placed intragastric balloons

Restrictive and Malabsorptive
• Biliopancreatic diversion (BPD) Duodenal Switch
• Roux Y gastric bypass (RYGB)
Restrictive and Malabsorptive

- Procedures combine effective methods of restriction in combination with a malabsorptive component
- Restrictive procedures alter the sensation of satiety
- Malabsorption due to shortened length of bowel to allow food and digestive enzymes to absorb
Restrictive and Malabsorptive

• Works through dual mechanisms – limited calorie intake and limited absorption of calories
• Are less subject to patient’s dietary compliance – patients will only absorb portions of every meal they consume.
• Requires nutritional supplementation and follow up

Restrictive and Malabsorptive

• Roux Y bypass is potentially best choice for reflux
• Lower risk of inadequate weight loss, weight recidivism
• Requires potential supplementation of iron, calcium, B12, and other micronutrients (fat soluble vitamins)
Goals

- Obesity over the last decade
- Surgery has become a safer management strategy
- Surgical options for management

<table>
<thead>
<tr>
<th>Medication</th>
<th>Preop Cost</th>
<th>1 Year Postop Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novalog</td>
<td>$260.42</td>
<td>discontinued</td>
</tr>
<tr>
<td>Lantus</td>
<td>$318.07</td>
<td>discontinued</td>
</tr>
<tr>
<td>Actos</td>
<td>$205.21</td>
<td>discontinued</td>
</tr>
<tr>
<td>Zocor</td>
<td>$17.80</td>
<td>discontinued</td>
</tr>
<tr>
<td>Zetia</td>
<td>$96.06</td>
<td>discontinued</td>
</tr>
<tr>
<td>Lisinopril</td>
<td></td>
<td>$10.24</td>
</tr>
<tr>
<td>Nexium</td>
<td></td>
<td>discontinued</td>
</tr>
</tbody>
</table>

Monthly cost of meds: $1067.90